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Abstract To investigate the role of opioids as direct modulators 
of the immune response, we have searched for expression of the 
recently cloned 6,/~ and K opioid receptors in immune cells. We 
have devised a reverse transcriptase-polymerase chain reaction 
strategy which specifically detects a region spanning putative 
transmembrane regions 2 to 7 for each transcript in both human 
and mouse immune cells. In human peripheral blood lymphocyte 
and monocyte preparations, 6 was undetectable while the g tran- 
script was present. The analysis of human cell lines revealed low 
but significant levels of 6 opioid receptor transcripts in T, B or 
monocyte cell lines while the K transcript was found in B cell lines 
only. Investigation of routine cells showed the presence of tran- 
script for the 6 receptor in splenocytes and in some T and B cell 
lines. Unexpectedly, no expression of the bt receptor was de- 
tected. Sequence analysis of PCR products demonstrated nucleo- 
tide identity between immune and neuronal transcripts, indicating 
that they derive from the same genes. In conclusion, our results 
lead to the identification of K and 6 opioid receptor transcripts 
in immune cells. 
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I. Introduction 
Opioids are involved in numerous physiological processes 
including pain control, response to stress, locomotion and cog- 
nition, as well as neuroendocrine, autonomic and immune 
physiology. The opioid system consists of a family of en- 
dogenous peptides which act through three classes of mem- 
brane receptors [1] refered to as/~, 8 and x. These receptors are 
also targets for exogenous opiate drugs and mediate their 
strong analgesic and psychotropic actions. The recent molecu- 
lar cloning of a mouse 8 opioid receptor from a neuroblastoma 
cell line [2,3] and the subsequent identification of homologous 
/1 [4] and x [5] cDNAs from rodent brain have demonstrated 
that opioid receptors in the nervous ystem belong to the G 
protein-coupled receptor superfamily with a putative seven 
transmembrane domain (Tm) topology. The pharmacology of
the three cloned receptors correlates well with the previous ¢t, 
8 and x classification [6] and their expression pattern parallels 
binding sites distribution i  the nervous ystem [7]. 
Evidence for a role ofopioids in the modulation of immunity 
has increased in the last years and multiple reports describe 
immunosuppressive or immunoenhancing effects of opioids in 
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PBL, peripheral blood lymphocytes; RT-PCR, reverse transcriptase- 
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both in vivo and in vitro models. It has been suggested that 
physiological s well as pathological situations which involve 
the opioid system such as stress, chronic pain treatment and 
drug addiction might lead to insufficient immune defense 
against infections or cancer (for reviews see [8-10]). In vivo 
effects of opioids may be mediated by opioid receptors of the 
nervous system that would in turn modulate glucocorticoid 
release, acting therefore indirectly on immune response [11]. 
Immunomodulation might also result from a direct action of 
opioids on immune cells, and in vitro studies uggest that im- 
mune cells themselves are responsive to opioids. Interestingly, 
the mode of action of opioids on these cells remains unclear and 
it has been suggested that it might differ from the opioid phar- 
macology classically described on neurons. Thus, most reports 
describe opioid effects on the biological activity of immune cells 
but few authors demonstrate high-affinity, subtype-specific and 
stereoselective opioid binding to these cells. Also, several re- 
ports have described receptors that do not meet the classical 
opioid criteria, particularly receptors which bind fl-endorphin 
in a non-naloxone r versible fashion [12-15] or which bind 
opiate alkaloids, but not opioid peptides, with moderate affin- 
ity [16,17]. 
The cloning of opioid receptors from the nervous ystem has 
provided molecular tools to probe opioid function. Therefore, 
to investigate he possibility that these receptors might be in- 
volved in the direct action of opioids on immune response, we 
have searched for their expression i  a wide repertoire of im- 
mune cells. This report presents our identification of 6- and x- 
but not/l-opioid receptor transcripts in some of these cells and 
provides the first molecular evidence for x-opioid receptor ex- 
pression in human immune cells and 8-opioid receptor expres- 
sion in murine immune cells. 
2. Materials and methods 
2.1. Normal immune ~ells 
Cells from spleen and lymph nodes of C57Bll6 x SJL mice (610 
weeks) were obtained as single cell suspensions and depleted from red 
cells by lysis with NH4CI. Murine spleen cells (2 x 106/ml) were cultured 
in vitro with concanavalin A (2,ug/ml, Sigma) in DMEM/10% fetal calf 
serum (FCS) (Gibco) for 3 days. Human PBL and monocytes from 
different donors for each cell preparation were depleted from red cells 
and granulocytes by cytapheresis and elutriation. Human PBL from 
one preparation (PBL 1) were cultured in vitro with phytohaemag- 
glutinin (2/~g/ml, Sigma) in RPMI 1640/10% FCS for 3 days. 
2.2. Cell lines 
SH-SY-5Y, Jurkat, CEM, MOLT-4, EBV and U937 cells were cul- 
tured in RPMI-1640 supplemented with 10% FCS. The three EBV cell 
lines were established from three individuals. HSB2 cells were grown 
in SMEM supplemented with 10% FCS. EL-4, 11-10, X63-IL-4, CH27 
and P388D, were cultured in DMEM-10% FCS, fl-mercaptoethanol 
(5 x 10 5 M), J774 cells in ~1900 supplemented with 10% FCS and 
CTLL cells in RPMI-1640 with 10% FCS, fl-mercaptoethanol (5 x 10 ' 
M) and interleukin 2.All culture media contained 500 U/ml penicillin, 
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100 yg/ml streptomycin, 40 yg/ml gentamycine and 2 mM glutamine 
and cultures were maintained at 37°C in 5% CO: in a humid atmos- 
phere. 
2.3. Reverse-transcriptase polymerase-chain-reaction 
Before RN A extraction, cells were washed two times with phosphate 
buffered saline and frozen at -80°C. Total cytoplasmic RNA was 
isolated by the guanidinium thiocyanate/phenol/chloroform method 
[18] and RNA integrity was confirmed by agarose gel electrophoresis. 
Complementary DNA (cDNA) was synthesized from 10 pg total RNA 
at 37°C Ibr 1 h using 200 ng random hexamer oligonucleotide and 400 
units of Moloney murine Leukemia Virus reverse transcriptase (BRL) 
in a reaction volume of 50 #1. Correct eDNA synthesis in every sample 
was controled by PCR analysis of ribosomal cDNAs (not shown). 
Opioid receptor transcripts were then amplified using sets of specific 
primers (Fig. 1) as follows: one tenth of the eDNA was amplified using 
the 77 aquaticus polymerase (Taq polymerase, 2 units, Cetus) for forty 
cycles (1 min 94°(7, I min 55°C, 1 min 72°C). RT-PCR was performed 
two to five times li)r each sample and for each receptor type. 
2.4. Southern bh~t analysis' 
One tenth of the PCR product was resolved by electrophoresis on 1% 
agarose gel and transfered onto Hybond N + nylon membrane (Amer- 
sham). PCR products were revealed by hybridization with 32p-labelled 
subtype-specific oligonucleotides (Fig. 1) followed by autoradiography. 
Southern blots were exposed 16 h at -80°C with intensifying screens. 
Opioid receptor transcripts appeared substantially more abundant in 
positive controls (brain, neuroblastoma and placenta) and exposure 
time lbr these samples was limited to 1.5 h to avoid overexposure. 
2.5. Chmh~g and sequencing o/'the PCR products 
PCR products were purified after 1% agarose gel electrophoresis 
(GeneClcan. Biol01 ). blunt-ended by treatment with DNA polymerase 
I (BiolabsL and inserted into EcoRV sites of the cloning vector 
pBluescript (Stratagene). Sequencing reactions were performed using 
the Sanger dideoxy nucleotide chain-termination method (Taq Dye 
Deoxy terminator Cycle sequencing Kit, Applied Biosystems, Inc.) and 
analysed on an automated DNA sequencer (373A DNA, Applied 
Bioystems Inc.) using fluorescently abeled nucleotides. 
3. Results 
3.1. P( 'R strateK!' 
In order to survey expression of the three cloned opioid 
receptors in murine and human immune cells, we have used a 
RT-PCR approach. For each receptor type (6, p and x), three 
specific oligonucleotides (A, B, and C, see Fig. 1) were designed 
according to previously reported nucleotide sequences 
[2.3,5,19 22] and on the basis of two requirements: A/B primer 
pairs span an intron to prevent any possible amplification 
from traces amounts of genomic DNA possibly present in RNA 
preparations, and also A, B and C sequences derive from re- 
gions which are highly divergent between 6, p and x receptors 
to exclude any possible hybridization across subtypes. PCR 
products were therefore obtained from A/B annealing to spe- 
cific cDNA molecules and subsequently submitted to Southern 
analysis, using radiolabelled oligonucleotide C as a probe, to 
increase the selectivity and the sensitivity of transcript detec- 
tion. The size of the obtained hybridizing PeR products were 
as expected from the known cDNA sequences, both in controls 
and in immune cells. Generally, the signal in immune cells was 
of considerable lower intensity as compared to that obtained 
from brain, neuroblastoma or placental positive controls. Re- 
suits are presented on Fig. 2 for human cells and on Fig. 3 for 
murine cells. 
3.2. Expression o/opioid receptors in human immune cells 
We have analysed normal human immune cell preparations 
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5'GAGAGCTCGCGGCCGCCAAGTACTTGATGGAAAACG3' 
5~GGCGGAAGCAGCGCTrGAAGTr3' 
5'CAGCGTCCAGACGATGACGA3' 
5'GAGAGCTCGCGGCCCGCTACCTGATGGGAACGTGC, C3' 
5'GGAAGCTrGAATrCGGA~TGTrCCCTAGTGT3' 
5'CTGATCACGATTCCAGAAACC3' 
5'GAGAGCTCGCGGCCGCGTCTACTTGATGAATFCTTGG3' 
5'GGAAGCTrGAATrCGGAAGCAGGATCCTGAACTG3' 
5'GCACCTCCCACAGCACAGCTGC3' 
ffagmentsize 
697 bp 
785 bp 
788 bp 
5'GAGAGCTCGCGGCCGCCAAGTACTTGATGGAAACG3' 
5'GGAAGCTrGAATI"CCTGAAGCTGCTGGGGTCTGGGCY 755 bp 
5'GGACATCGACCGCK2GCGACC3' 
5'GAGAGCTCGCGGCCGCGTCTACTTGATGAATTCCTGGY 
5'GGAAGC'I'rGAATrCCGAGTGGAGTrTrGTTGCTC Y 758 bp 
C 5'G CCTTGGTTACAATCCCCAGAY 
A 5'G AGAGCTCGCGGCCrCGTCTACTTGATGAATTCCTGG3' 
B 5'GGAAGCTTGAATrCGGTAAGCAGGATCCTGAACTG3' 789 bp 
C 5'GCACCTCCCACAGCACAGCTGC 3 
ATG FGA 
A C B 
Fig. 1. RT-PCR strategy for the detection opioid receptor mRNA in 
immune cells. Nucleotide sequence of the primers are derived from 
published opioid receptor sequences as described in the section 3. Prim- 
ers A (forward) and B (reverse) have been used for PCR amplification 
and primers C for hybridization. Expected PCR fragment sizes for each 
combination are indicated. A scheme of the cDNA is presented below, 
with putative Tm domains as grey boxes and splice junctions hown by 
v. The localization of the primers A, B and C is shown, relative to the 
eDNA coding sequence. 
for the presence of opioid receptor mRNA,  including unstimu- 
lated peripheral blood lymphocytes (PBL1, 2 and 3) and mon- 
ocytes (monocytes 1, 2 and 3) from three individuals. We have 
detected no mRNA for 6 or p receptors in these cells. In con- 
trast, one out of three lymphocyte preparations (PBL2) and two 
out of three monocyte preparations (monocyte 1 and 2) con- 
tained significant levels of mRNA for the x receptor. Using 
phytohaemagglutinin, we stimulated a PBL preparation which 
exhibited no detectable opioid receptor expression in the resting 
state (PBLI). Analysis of this new cell preparation (PBL-PHA) 
did not show any specific PCR product either, indicating that 
cell activation did not induce opioid receptor expression. The 
observation of *c transcript in some but not all preparations 
suggests possible interindividual variability of x receptor ex- 
pression in human lymphocytes and monocytcs. 
We have analyzed several cell lines derived fl:om tumors, 
including one monocyte-like cell line (U937), three pre-T cell 
lines (MOLT-4, CEM, HSB2), one helper T lymphocyte line 
(Jurkat), and three EBV-transformed B cell lines. All of them, 
except the Jurkat cell line, showed significant levels of PCR 
product for the 6 receptor. The transformed EBV B cell lines 
display variable levels of transcript for the K receptor, while all 
other cell lines are negative. None of the cell lines express 
detectable levels of mRNA for the p receptor. 
We have subcloned and sequenced K receptor mRNA-de- 
rived PCR products obtained t'rom PBL2, monocyte2 and 
EBV2 cells. Nucleotide sequences were identical to those of 
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Fig. 2. RT-PCR detection of opioid receptors mRNAs in human im- 
mune cells. Positive controls were RNA from human cortex for the 
three opioid receptor types (positive control 1) or from SH-SY-5Y cells 
for 8 and kt receptors (positive control 2) and placenta for x the receptor 
(positive control 2). In negative controls cDNA was omitted, i¢ receptor 
mRNA-derived PCR products indicated by arrows have been cloned, 
sequenced and found identical to brain-derived PCR products. 
opioid receptors cloned from the nervous system (not shown). 
This result suggests that the human x receptor cDNA clone 
previously described in the nervous ystem and the transcripts 
detected in the present analysis derive from the same gene. 
3.3. Expression of opioid receptors in murine immune cells 
In mouse, we have analysed spleen cells and lymph node cells 
which represent normal immune cell populations. We have 
found a strong RT-PCR signal for the 6 receptor mRNA from 
two out of three spleen cell preparations, whereas there was no 
detectable PCR product for the/~ and x receptors from any of 
these samples. 
We have tested the murine T cell lymphoma EL-4, the cyto- 
toxic T cell line CTLL, the T cell hybridomas 11.10 and X63- 
IL-4, the B cell lymphoma CH27, the B cell hybridoma 25-9-17S 
and the macrophage cell lines P388D t and J774 for the expres- 
sion of opioid receptors. Significant mRNA levels were found 
for the ~ receptor in two T cell lines (EL4 and 11.10) as well 
as in a B cell line (CH27). No~t and x receptors transcripts were 
detectable by our method in any of the cell lines analysed. 
Analysis of PCR products obtained from spleen 1 and EL-4 
RNA samples demonstrates identical nucleotide sequence to 
that of the mouse neuronal 6 receptor (not shown). Hence, the 
6 receptor transcript expressed in murine immune cells derives 
from the same gene as the cloned neuronal receptor. 
4. Discussion 
In this report, we show evidence for the expression of 6-and 
x-opioid receptor mRNAs in immune cells (See summary in 
Table 1). Their detection is based upon sequence homology 
with the recently cloned opioid receptors and the RT-PCR 
technology. We also provide molecular characterization f the 
almost entire coding region of these mRNAs, by sequence anal- 
ysis of PCR products. Nucleotide identity with neuronal 
cDNAs strongly suggests that they are transcribed from the 
known 6- and x-opioid receptor genes. 
Our study shows that opioid receptor transcripts are not 
widely distributed in immune cells. We have investigated a large 
immune cell repertoire and their occurrence accross the various 
cell types does not necessarily correlate with the opioid phar- 
macology described in the litterature. The absence of the/~ 
transcript appears inconsistant with studies reporting the exis- 
tence of a/,t-specific pharmacology, such as morphine effects 
on human lymphocytes [23 25], binding of dihydromorphine 
on human monocytes [26], [3H]BIT (2-(p-ethoxy-benzyl)- 
1-(N,N-diethylamino)-ethyl-5-isothiocyanatobenzimidazole) 
binding or the biological action of morphine and DAMGO on 
murine splenocyte activity [27,28]. Also, a ~ receptor has been 
described in human lymphocytes [29 32] whereas no 6 mRNA 
could be detected from human PBL in our study. Similarly, the 
x-agonist U50488 was reported to inhibit significantly mouse 
splenocyte activity [28] while no x transcript was found in our 
analysis of murine spleen RNA. Another discrepancy is our 
finding that none of the cloned opioid receptor is expressed in 
J774 cells, which have been shown to effectively respond to 
Dynorphin A in a naloxone-reversible manner [33]. This appar- 
ent lack of correspondence might arise from high interindivid- 
ual variability in humans, as was previously shown for nalox- 
one binding on T lymphocytes [34] or opioid effects on PBL 
Table 1 
Summary of opioid receptor expression in human and mouse immune 
cells 
6 /~ x 
Human 
Cortex +++ +++ +++ 
PBL 1/2/3 - / - / -  - / - / -  - /+/-  
PBL-PHA - - - 
Monocytes 1/2/3 - / - / -  - / - / -  +/+/- 
T cell lines 
MOLT-4 + 
HSB2 + 
CEM + 
Jurkat 
B cell line 
EBV1/2/3 
Monocyte line 
U937 
Mouse 
Brain 
Spleen 1/2/3 
Lymph nodes 
+/+/+ - / - / -  +/++/+ 
+ 
+++ +++ +++ 
++/-/++ - / - / -  - / - / -  
T cell lines 
EL-4 ++ 
ll.10 + 
CTLL 
X63-IL-4 
B cell lines 
CH27 ++ 
25-9-17S 
Macrophage lines 
P388D1 
J774 
RT-PCR signal intensity is indicated as +++: very strong, ++: moder- 
ate, +: very low, - undetectable. For human PBL and monocyte prep- 
arations, samples from three individuals have been tested, while for 
mouse spleen cells, three pools of fifteen spleens have been examined. 
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Fig. 3. RT-PCR detection of opioid receptors mRNA expression in 
mouse immune cells. Positive control was mouse brain RNA for all 
receptor types and negative controls were performed without eDNA 
temp!ate. Arrows show a receptor mRNA-derived PCR products which 
have been cloned, sequenced and found identical to brain derived PCR 
products. 
proliferation [35], or be related to strain-dependent immune 
response in mice [36], or finally be due to the existence of 
divergent subclones in the model cell lines that we have used. 
A more likely possibility is that the/,t, a and x opioid effects 
which have been defined on a pharmacological basis, are 
mediated by receptors that are different from the cloned 
receptors. 
In line with this hypothesis is also the description of 'non- 
classical' opioid receptors on immune cells with a pharmacof  
ogical profile different from the typical ~, 6 and ~c receptors. 
Particularly, fl-endorphin has been shown to interact with 
human PBL [37], human monocytes [38], U 937 [15], and EL-4 
cells [39] in a naloxone non-reversible fashion, thus defining a 
non-opiate site. This pharmacology is believed to result from 
the interaction of fl-endorphin with a receptor which has not 
yet been characterized at the molecular level. Interestingly, in 
these cells, we have identified 6 or ~c mRNAs for the cloned 
receptors. It would be interesting to investigate further if the 
putative ~ and t¢ mRNA-encoded receptor proteins do partici- 
pate to fl-endorphin binding, possibly in association with other 
membrane proteins. Another type of unusual opioid pharma- 
cology has been described in human monocytes and J774 cells, 
as well as in some neuroblastoma cells and the existence of 
receptors that bind opioid alkaloids but not opioid peptides has 
been suggested [17]. These receptors, refered to as ~3, would 
be different from the classically described/a receptor and could 
well be important in mediating opiate drugs action on the 
immune system. The demonstration of the existence of /a3 
opioid receptors in J774 cells, and our results showing no ~-, 
6- or x-opioid receptor transcripts in these cells, again supports 
the hypothesis of the existence of opioid receptors which derive 
from genes unrelated to the known ~, 6 and x genes. 
Some of our findings confirm previously described opioid 
receptors in immune cells. The observation of significant levels 
of mRNA encoding the cloned x receptor human PBL in our 
study is in accordance with the demonstration that CD4 + 
human lymphocytes express ~cl binding sites [40]. Also we have 
found transcripts for the ~ receptor in mouse spleen RNA, and 
this finding is consistent with reports that demonstrated the 
presence of 6 receptors on mouse cells [41,29] or rat splenocytes 
[42]. Finally the 6 transcript found in the MOLT-4 cell line 
might be responsible for the expression of FITC-naltrexone 
and [3H]superfit (cis-(+)-3-methylfentanylisothiocyanate) bind- 
ing sites previously described on these cells [43]. 
In normal immune cells, we have not identified transcripts 
for identical opioid receptor subtypes in mouse and humans. 
Human PBL express significant levels of it- receptor mRNA 
while murine splenocytes express a receptor mRNA only. Be- 
yond the species difference, the occurrence of distint receptor 
types might originate from the different tissue origin of cell 
preparations, as examplified by the report of differential effects 
of morphine in circulating lymphocytes compared to splenic 
lymphocytes in rat [44]. Our preparations of normal human 
immune cells are blood circulating cells while samples for nor- 
mal murine cells are obtained from the spleen. Our results in 
mouse and humans are therefore not strictly comparable. One 
should note however that the a receptor is expressed in many 
cell lines in both mammals, suggesting that the a receptor is 
likely to play a role in immune cells independently from the 
species. 
In summary, our study leads to several conclusions: (i) Anal- 
ysis of opioid receptor expression in a wide variety of cells 
underscores a possible role for ~ and x receptors in immune 
cells. (ii} The absence of/a-opioid receptor transcript and the 
restricted expression pattern o fx  and ~ receptor, however, does 
not seem to correlate with the multiple effects of opioids de- 
scribed in the litterature. Therefore, the hypothesis that yet 
uncloned opioid receptors might be responsible l\~r opioid ac- 
tion on immune cells is a reasonnable possibility. (iii) Murinc 
T and B cell lines (EL-4 and CH27) as well as human EBV- 
transformed B cells express ubstantial levels of ~ and ~" recep- 
tors respectively (see Table 1 ), and may be now used as model 
cell lines to study the mechanism of action of opioids and thc 
regulation of opioid receptor expression in immune cells at the 
molecular lexel. (iv) Our results obtained with normal human 
immune cells, may now be extended to the analysis of drug- 
addicted or morphin-treated individuals and allow to enter the 
physiopathology of opioid receptors m the innnune system. 
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